Literature DB >> 28970473

Patient-derived hiPSC neurons with heterozygous CNTNAP2 deletions display altered neuronal gene expression and network activity.

Erin Flaherty1,2, Rania M Deranieh3, Elena Artimovich3, Inkyu S Lee1,2, Arthur J Siegel4, Deborah L Levy5, Michael W Nestor6, Kristen J Brennand7,8,9.   

Abstract

Variants in CNTNAP2, a member of the neurexin family of genes that function as cell adhesion molecules, have been associated with multiple neuropsychiatric conditions such as schizophrenia, autism spectrum disorder and intellectual disability; animal studies indicate a role for CNTNAP2 in axon guidance, dendritic arborization and synaptogenesis. We previously reprogrammed fibroblasts from a family trio consisting of two carriers of heterozygous intragenic CNTNAP2 deletions into human induced pluripotent stem cells (hiPSCs) and described decreased migration in the neural progenitor cells (NPCs) differentiated from the affected CNTNAP2 carrier in this trio. Here, we report the effect of this heterozygous intragenic deletion in CNTNAP2 on global gene expression and neuronal activity in the same cohort. Our findings suggest that heterozygous CNTNAP2 deletions affect genes involved in neuronal development and neuronal activity; however, these data reflect only one family trio and therefore more deletion carriers, with a variety of genetic backgrounds, will be needed to understand the molecular mechanisms underlying CNTNAP2 deletions.

Entities:  

Year:  2017        PMID: 28970473      PMCID: PMC5624885          DOI: 10.1038/s41537-017-0033-5

Source DB:  PubMed          Journal:  NPJ Schizophr        ISSN: 2334-265X


Short Report

The shared genetic architecture underlying neuropsychiatric disorders implicates common molecular mechanisms.[1] For example, while homozygous null mutations in CNTNAP2 lead to cortical dysplasia-focal epilepsy syndrome,[2, 3] heterozygous intragenic deletions are associated with schizophrenia, intellectual disability, language deficits, seizures, and autism traits.[4] Critically, CNTNAP2 variants are not completely penetrant.[2, 5] Animal studies indicate a role for CNTNAP2 in axon guidance, dendritic arborization, and synaptogenesis.[6-8] We obtained fibroblast samples from a family trio with two carriers of heterozygous intragenic CNTNAP2 deletions, one affected and one unaffected, and an unaffected non-carrier control (Table 1). The CNTNAP2 carriers display discordant clinical phenotypes; the daughter (DL7078) presented with schizo-affective disorder (depressed subtype) while the father (DL8735) was neurotypical.[9] We previously used sendai viral vectors to reprogram fibroblasts from this trio into hiPSCs that were then differentiated via dual-SMAD induction into NPCs and neurons. We characterized decreased migration in NPCs and allele-biased expression of the mutant CNTNAP2 transcript by qPCR in neurons from the affected CNTNAP2 carrier in this trio.[9] Here, we report the effect of this heterozygous intragenic deletion in CNTNAP2 on global gene expression and neuronal activity in this same cohort.
Table 1

Available clinical information on hiPSC donors

Patient IDSourcehiPSC LineFamilySexDxAge of OnsetIQClozapine ResponseFamily History
DL7078McLeans7078 hiPSC#BProbandFSA18.9100Y
DL8735McLeans8735 hiPSC#HFatherMControln/a120n/aSA
DL5535McLeans5535 hiPSC#2MotherFControln/a95n/aSA
NSB3113NIH3113 hiPSC#1Non-relativeFControln/a123n/an/a
Available clinical information on hiPSC donors CNTNAP2 is highly expressed in Ngn2-induced neurons, a population of nearly pure excitatory neurons,[10] relative to hiPSC-derived NPCs[11] and hiPSC-astrocytes[12] (qPCR FC = 82.5, p < 0.0001, ANOVA with Tukey’s Post-Hoc) (Fig. 1a). RNA was harvested after 21 days of Ngn2-induction. The New York Genome Center prepared RNAseq libraries using the Kapa Total 350 bp kit, followed by 2 × 125 bp Illumina RNA sequencing to a read depth of 40 M reads per sample on the HiSeq 2500.
Fig. 1

CNTNAP2 expression in excitatory neurons induced from family trio. a By qPCR, CNTNAP2 expression is significantly increased in Ngn2-induced neurons compared to neural progenitor cells (NPCs) and hiPSC-derived astrocytes. Data reflects biological triplicate samples from one hiPSC line derived from each of three healthy controls (mean +/− s.e.m). b RNA sequencing data shows total CNTNAP2 expression is increased in deletion carriers compared with non-carrier control (mean +/− s.e.m). c Genes differentially expressed in CNTNAP2 deletion carriers are enriched for genes involved in DNA binding and central nervous system development. * p < 0.05, *** p < 0.001

CNTNAP2 expression in excitatory neurons induced from family trio. a By qPCR, CNTNAP2 expression is significantly increased in Ngn2-induced neurons compared to neural progenitor cells (NPCs) and hiPSC-derived astrocytes. Data reflects biological triplicate samples from one hiPSC line derived from each of three healthy controls (mean +/− s.e.m). b RNA sequencing data shows total CNTNAP2 expression is increased in deletion carriers compared with non-carrier control (mean +/− s.e.m). c Genes differentially expressed in CNTNAP2 deletion carriers are enriched for genes involved in DNA binding and central nervous system development. * p < 0.05, *** p < 0.001 We queried the expression of CNTNAP2 in Ngn2-induced neurons from each member of this family trio, hypothesizing that heterozygous intragenic deletions may affect the expression of CNTNAP2. Surprisingly, overall CNTNAP2 expression was increased in the CNTNAP2 deletion carriers compared with the non-carrier mother (log2FC = 1.24, padj = 0.003) (Fig. 1b). Differential expression analysis was performed using DESeq2[13] and the top 500 differentially expressed genes were used to perform gene ontology using DAVID[14, 15] (SI Table 1). The most significant subset of genes mapped to terms relating to DNA binding and central nervous system (CNS) development (FC = 1.8, p < 0.00001 and FC = 1.9, p = 0.0003) (Fig. 1c; SI Table 2). Within the gene subset involved in CNS development, there are some interesting candidate genes such as CNTN6 and CNTN4, which are involved in regulating cell surface interactions during nervous system development and are also thought to be important in synaptogenesis (SI Table 3 ). Given the differences in gene expression of critical neuronal and synaptic genes, we applied an Axion multi-electrode array (MEA) (see similar applications to Amyotrophic Lateral Sclerosis[16] and Parkinson’s disease[17]) to record population-wide neuronal activity under conditions similar to those used in our RNAseq analyzes. 21-day-old Ngn2-induced neurons from both the affected (daughter, DL7078) and unaffected (father, DL8735) CNTNAP2 deletion carriers showed significantly increased spontaneous network level activity (an increase of 210 and 253%, respectively) relative to the non-carrier (mother, DL5535) and an unaffected unrelated control (female, NSB3113) (N = 12 wells/condition; p < 0.001, ANOVA with Tukey’s Post-Hoc) (Fig. 2a). These results were confirmed in hiPSC-derived forebrain neuron populations, which are comprised of a mixture of mature and immature excitatory neurons, inhibitory neurons and astrocytes, with the majority of cells presumed to be excitatory neurons.[18, 19] Here, NPCs were seeded (65,000 cells/mL) onto 12-well MEA plates and differentiated for 28 days; hiPSC-derived neurons from the affected and unaffected CNTNAP2 deletion carriers showed significantly increased spontaneous population wide neuronal activity relative to the non-carrier mother (increases of 344 and 182% relative to the non-carrier mother; N = 12 wells/condition; p < 0.001, ANOVA with Tukey’s Post-Hoc) (Fig. 2a, b). All measurements were performed as biological triplicates for each hiPSC line and averaged across experiments. In both populations, neurons robustly stained for neuronal markers βIII-TUBULIN, NeuN, and MAP2 (representative images in Fig. 2c).
Fig. 2

hiPSC-derived neurons from CNTNAP2 carriers show increased neuronal activity compared to control. a Summary data of population-wide MEA spike frequency of individuals in the family trio in both the Ngn2-induced neurons (green) and hiPSC-derived forebrain mixed neuronal populations (red) reveal significantly increased synaptic activity in the CNTNAP2 deletion carriers. *** p < 0.001 b Representative traces of population-wide neuronal activity measured by MEA. c Representative staining of directed differentiation neurons (left and center) at Day28 for general neuronal markers on MEA plates demonstrate normal expression of TUJ1 (green), NEUN (red); (left, 100X), as well as VGLUT1 (blue); (center, 200X)) (s.b. left = 100 μM; right = 50 μM). Representative staining of Ngn2-induced neurons (right) for MAP2 and, as well as expression of hNgn2-eGFP-PuroR (addgene #79823) at Day21 (right, 200X) (s.b. = 40 μM)

hiPSC-derived neurons from CNTNAP2 carriers show increased neuronal activity compared to control. a Summary data of population-wide MEA spike frequency of individuals in the family trio in both the Ngn2-induced neurons (green) and hiPSC-derived forebrain mixed neuronal populations (red) reveal significantly increased synaptic activity in the CNTNAP2 deletion carriers. *** p < 0.001 b Representative traces of population-wide neuronal activity measured by MEA. c Representative staining of directed differentiation neurons (left and center) at Day28 for general neuronal markers on MEA plates demonstrate normal expression of TUJ1 (green), NEUN (red); (left, 100X), as well as VGLUT1 (blue); (center, 200X)) (s.b. left = 100 μM; right = 50 μM). Representative staining of Ngn2-induced neurons (right) for MAP2 and, as well as expression of hNgn2-eGFP-PuroR (addgene #79823) at Day21 (right, 200X) (s.b. = 40 μM) Our genetic analyzes and functional assays together show that heterozygous deletion of CNTNAP2 may impact neuronal activity. The significant increase in spontaneous spiking activity in the unaffected carrier father and carrier daughter may underlie aspects of the aberrant behavior displayed by the proband. Additionally, this alteration in spike activity may in part explain observations of disrupted neuronal synchrony in CNTNAP2-null mice.[6] Here we demonstrated that hiPSC-derived neurons from individuals with heterozygous intragenic deletions in CNTNAP2 display differential expression of genes involved in synaptic transmission and altered neuronal activity, consistent with reports of disrupted cortical neuronal activity in CNTNAP2-null mice,[6] and potentially independent of clinical outcome. Our report reflects results from just one family trio; a greater variety of disease-associated CNTNAP2 mutations, on an array of genetic backgrounds, will be needed to understand the full breath of genotype-phenotype relationships with respect to CNTNAP2.[18, 20–22]

Ethical approval

The methods were performed in accordance with relevant guidelines and regulations and approved by the McLean Hospital Institutional Review Board. Participants were subject to informed and written consent.

Data availability

All case and control hiPSCs, which have been mycoplasma tested, will be deposited with the NIMH Center For Collaborative Studies Of Mental Disorders At RUCDR. RNAseq data for CNTNAP2 carrier and non-carrier neurons (GEO GSE102838) have been deposited at the GeneExpression Omnibus (GEO) repository. Antibodies used in this study are: βIII-TUBULIN (1:500; Chicken; Biolegend; 801201), NeuN(1:100; Rabbit; Abcam; ab104225), MAP2 (1:500; Chicken; Abcam; ab5392). SI Tables 1-3
  22 in total

1.  iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease.

Authors:  Chris M Woodard; Brian A Campos; Sheng-Han Kuo; Melissa J Nirenberg; Michael W Nestor; Matthew Zimmer; Eugene V Mosharov; David Sulzer; Hongyan Zhou; Daniel Paull; Lorraine Clark; Eric E Schadt; Sergio Pablo Sardi; Lee Rubin; Kevin Eggan; Mathew Brock; Scott Lipnick; Mahendra Rao; Stephen Chang; Aiqun Li; Scott A Noggle
Journal:  Cell Rep       Date:  2014-11-06       Impact factor: 9.423

Review 2.  Modeling heterogeneous patients with a clinical diagnosis of schizophrenia with induced pluripotent stem cells.

Authors:  Kristen J Brennand; Melissa A Landek-Salgado; Akira Sawa
Journal:  Biol Psychiatry       Date:  2013-11-15       Impact factor: 13.382

3.  A guide to generating and using hiPSC derived NPCs for the study of neurological diseases.

Authors:  Aaron Topol; Ngoc N Tran; Kristen J Brennand
Journal:  J Vis Exp       Date:  2015-02-21       Impact factor: 1.355

4.  Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2.

Authors:  Kevin A Strauss; Erik G Puffenberger; Matthew J Huentelman; Steven Gottlieb; Seth E Dobrin; Jennifer M Parod; Dietrich A Stephan; D Holmes Morton
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

Review 5.  Shining a light on CNTNAP2: complex functions to complex disorders.

Authors:  Pedro Rodenas-Cuadrado; Joses Ho; Sonja C Vernes
Journal:  Eur J Hum Genet       Date:  2013-05-29       Impact factor: 4.246

6.  Candidate autism gene screen identifies critical role for cell-adhesion molecule CASPR2 in dendritic arborization and spine development.

Authors:  Garret R Anderson; Timothy Galfin; Wei Xu; Jason Aoto; Robert C Malenka; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-16       Impact factor: 11.205

7.  Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons.

Authors:  Brian J Wainger; Evangelos Kiskinis; Cassidy Mellin; Ole Wiskow; Steve S W Han; Jackson Sandoe; Numa P Perez; Luis A Williams; Seungkyu Lee; Gabriella Boulting; James D Berry; Robert H Brown; Merit E Cudkowicz; Bruce P Bean; Kevin Eggan; Clifford J Woolf
Journal:  Cell Rep       Date:  2014-04-03       Impact factor: 9.423

8.  Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia.

Authors:  K Brennand; J N Savas; Y Kim; N Tran; A Simone; K Hashimoto-Torii; K G Beaumont; H J Kim; A Topol; I Ladran; M Abdelrahim; B Matikainen-Ankney; S-h Chao; M Mrksich; P Rakic; G Fang; B Zhang; J R Yates; F H Gage
Journal:  Mol Psychiatry       Date:  2014-04-01       Impact factor: 15.992

9.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nucleic Acids Res       Date:  2008-11-25       Impact factor: 16.971

Review 10.  Genomic insights into the overlap between psychiatric disorders: implications for research and clinical practice.

Authors:  Joanne L Doherty; Michael J Owen
Journal:  Genome Med       Date:  2014-04-28       Impact factor: 11.117

View more
  10 in total

1.  Intragenic Deletions May Involve Enhancer Sequences and Alter CNTNAP2 Expression.

Authors:  Martin Poot
Journal:  Mol Syndromol       Date:  2018-05-09

2.  CRISPR-based functional evaluation of schizophrenia risk variants.

Authors:  Prashanth Rajarajan; Erin Flaherty; Schahram Akbarian; Kristen J Brennand
Journal:  Schizophr Res       Date:  2019-07-03       Impact factor: 4.939

3.  Transcription-associated DNA DSBs activate p53 during hiPSC-based neurogenesis.

Authors:  Nadine Michel; Heather M Raimer Young; Naomi D Atkin; Umar Arshad; Reem Al-Humadi; Sandeep Singh; Arkadi Manukyan; Lana Gore; Ian E Burbulis; Yuh-Hwa Wang; Michael J McConnell
Journal:  Sci Rep       Date:  2022-07-15       Impact factor: 4.996

4.  An integrated biomanufacturing platform for the large-scale expansion and neuronal differentiation of human pluripotent stem cell-derived neural progenitor cells.

Authors:  Gayathri Srinivasan; Daylin Morgan; Divya Varun; Nicholas Brookhouser; David A Brafman
Journal:  Acta Biomater       Date:  2018-05-15       Impact factor: 8.947

Review 5.  Investigation of Schizophrenia with Human Induced Pluripotent Stem Cells.

Authors:  Samuel K Powell; Callan P O'Shea; Sara Rose Shannon; Schahram Akbarian; Kristen J Brennand
Journal:  Adv Neurobiol       Date:  2020

6.  Robust Generation of Person-Specific, Synchronously Active Neuronal Networks Using Purely Isogenic Human iPSC-3D Neural Aggregate Cultures.

Authors:  Julia Izsak; Henrik Seth; Mats Andersson; Dzeneta Vizlin-Hodzic; Stephan Theiss; Eric Hanse; Hans Ågren; Keiko Funa; Sebastian Illes
Journal:  Front Neurosci       Date:  2019-04-24       Impact factor: 4.677

Review 7.  New considerations for hiPSC-based models of neuropsychiatric disorders.

Authors:  Gabriel E Hoffman; Nadine Schrode; Erin Flaherty; Kristen J Brennand
Journal:  Mol Psychiatry       Date:  2018-02-26       Impact factor: 15.992

Review 8.  Exploring the mechanisms underlying excitation/inhibition imbalance in human iPSC-derived models of ASD.

Authors:  Lorenza Culotta; Peter Penzes
Journal:  Mol Autism       Date:  2020-05-11       Impact factor: 7.509

9.  In Vitro Modeling of the Bipolar Disorder and Schizophrenia Using Patient-Derived Induced Pluripotent Stem Cells with Copy Number Variations of PCDH15 and RELN.

Authors:  Takaya Ishii; Mitsuru Ishikawa; Koki Fujimori; Takuji Maeda; Itaru Kushima; Yuko Arioka; Daisuke Mori; Yuhki Nakatake; Bun Yamagata; Shintaro Nio; Takahiro A Kato; Nan Yang; Marius Wernig; Shigenobu Kanba; Masaru Mimura; Norio Ozaki; Hideyuki Okano
Journal:  eNeuro       Date:  2019-10-17

10.  Investigation of de novo mutations in a schizophrenia case-parent trio by induced pluripotent stem cell-based in vitro disease modeling: convergence of schizophrenia- and autism-related cellular phenotypes.

Authors:  Edit Hathy; Eszter Szabó; Nóra Varga; Zsuzsa Erdei; Csongor Tordai; Boróka Czehlár; Máté Baradits; Bálint Jezsó; Júlia Koller; László Nagy; Mária Judit Molnár; László Homolya; Zsófia Nemoda; Ágota Apáti; János M Réthelyi
Journal:  Stem Cell Res Ther       Date:  2020-11-27       Impact factor: 6.832

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.